12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

APG101: Phase II data

An open-label, international Phase II trial in 83 patients with GBM showed that weekly IV APG101 plus radiotherapy as second-line treatment met the primary endpoint of PFS rate at 6 months vs. radiotherapy alone. Apogenix said the endpoint was considered met if the percentage...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >